Visiox Pharmaceuticals
Biotechnology, 303 S Broadway, Tarrytown, New York, 27703, United States, 1-10 Employees
Phone Number: +19*********
Who is VISIOX PHARMACEUTICALS
Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need o...
Read More
-
Headquarters: 303 S Broadway, Tarrytown, New York, 27703, United States
-
Date Founded: 2022
-
Employees: 1-10
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 3851
|
NAICS Code: 339115 |
Show More
Does something look wrong? Fix it. | View contact records from VISIOX PHARMACEUTICALS
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Visiox Pharmaceuticals
Answer: Visiox Pharmaceuticals's headquarters are located at 303 S Broadway, Tarrytown, New York, 27703, United States
Answer: Visiox Pharmaceuticals's phone number is +19*********
Answer: Visiox Pharmaceuticals's official website is https://visioxpharma.com
Answer: Visiox Pharmaceuticals's revenue is $100 Million to $250 Million
Answer: Visiox Pharmaceuticals's SIC: 3851
Answer: Visiox Pharmaceuticals's NAICS: 339115
Answer: Visiox Pharmaceuticals has 1-10 employees
Answer: Visiox Pharmaceuticals is in Biotechnology
Answer: Visiox Pharmaceuticals contact info: Phone number: +19********* Website: https://visioxpharma.com
Answer: Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals. Our first asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. Our second asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain. Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month